Shanghai, China, March 5, 2024 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases announced that the data from the international multicenter Phase III clinical study of its non-surgical treatment for cervical HSIL product APL-1702 will be presented as an oral presentation at the 2024 Annual Meeting of the Society of Gynecologic Oncology (SGO) in San Diego, United States, on March 17, 2024.
Dr.Wang Yue, Henan Provincial People’s Hospital
Dr. Wang Yue, Director of the Department of Obstetrics and Gynecology, Director of the Obstetrics and Gynecology Teaching and Research Office from Henan Provincial People’s Hospital, Chairman of the Obstetrics and Gynecology Branch of the Henan Medical Association, Incoming Chairman of the Obstetrics and Gynecology Oncology Branch of the Henan Medical Association, and Vice Chairman of the Obstetrics and Gynecology Physicians Branch of the Henan Medical Association, from Henan Provincial People’s Hospital, will be the speaker.
About Asieris
Founded in March 2010, Asieris Pharmaceuticals (Stock Code: 688176.SH) is a global biopharmaceutical company committed to the discovery, development, and commercialization of innovative drugs for the treatment of genitourinary tumors and related diseases. Our mission is to enhance human health and uphold patient dignity. We aspire to be a global pharmaceutical leader, integrating research and development (R&D), manufacturing, and commercialization to deliver top-tier, integrated diagnostic and treatment solutions for patients both in China and around the world.
Asieris has been advancing its proprietary R&D platform and core technologies, pioneering new mechanisms of action, and conducting efficient screening and evaluation of drug candidates. With a robust in-house R&D system and a wealth of expertise in global drug development, we are dedicated to introducing first-in-class drugs and innovative products, addressing significant unmet medical needs in our areas of specialization.
In our pursuit of excellence in treating genitourinary diseases, Asieris actively enhances its pipeline through proprietary R&D endeavors and strategic partnerships. We remain at the forefront of emerging technologies and therapeutic advances. Our approach is both proactive and forward-thinking, focusing on identifying and addressing unmet clinical needs. We aim to develop an exceptional portfolio encompassing both diagnosis and treatment, striving to improve the lives of more patients in China and across the globe.
